Acquiring Small and Medium-Sized Companies: A Study of Corporate Decision Behavior

This field research study investigated corporate acquisition decisions made by managers in U.S. manufacturing and conglomerate firms. The introductory chapters review organizational decision theories and empirical research on organizational and acquisition decision making. The thesis presents and investigates hypotheses for two descriptive models: a prediction model and a decision-process model. Through mail questionnaires, data were gathered about 28 acquisitions completed between October 1, 1979 and March 31, 1980. Managers were asked for retrospective information about decision activities and for a current assessment of the acquired company\u27s performance . Twenty-six companies made the acquisitions: nine very large companies with 1979 sales of more than $450 million and seventeen smaller companies. Of the 28 acquired companies, 14 had 1979 sales of$1 to $10 million, 13 had sales of$10 to $35 million, and one had sales of more than$350 million. The results of correlation and regression analyses indicate that moderate levels of participation in acquisition subdecisions and direct contact with the prospect are related to successful acquisitions, but higher levels of both activities are related to lower levels of success. Also, increased participation did not increase the perceived effectiveness of implementation activities. The amount of formal analytical activity and CEO involvement are not related to successful acquisitions. CEO involvement seems to depend on the size of the acquiring company, with CEOs in smaller companies more involved in making small and medium-sized acquisitions. Managers use more complex and extensive decision processes when an unrelated business is investigated, but the process is apparently often ineffective. Firms that had made more acquisitions also had different decision processes, including lower levels of participation and less use of information sources. Both experience making acquisitions and acquiring a related business are good predictors of a successful acquisition. Finally, a planned search for prospects is not related to more successful acquisitions. Only initiation by an unusual source alters the decision process, and then more CEO involvement and intensive search occur

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.

INTRODUCTION: The glucagon-like peptide-1 receptor agonists liraglutide and lixisenatide are effective at reducing glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Although liraglutide has demonstrated superior efficacy in head-to-head clinical trials, real-world evidence of comparative effectiveness is lacking. This observational study aimed to assess the effectiveness of liraglutide versus lixisenatide in UK clinical practice. METHODS: Electronic medical records from The Health Improvement Network (THIN) UK primary care database were analyzed. Patients aged ≥18 years, diagnosed with T2DM, and prescribed liraglutide or lixisenatide between 01 May 2013 and 31 December 2015 were included in the study. Adjusted linear regression models compared the difference in mean change in HbA1c, body mass index (BMI), and systolic blood pressure (SBP) after 12-month follow-up. The proportion of patients achieving glycemic control (HbA1c 1%; and weight reduction ≥3% within 12 months were determined. Cox proportional hazards modeling was used to evaluate the effect of treatment on time to achieving HbA1c and weight reduction targets. Healthcare resource use (HCRU) (GP, secondary care, hospitalizations) was compared using analysis of covariance. RESULTS: The primary outcome was assessed in 579 liraglutide and 213 lixisenatide new users. Fully adjusted linear regression indicated that liraglutide reduced HbA1c significantly more than lixisenatide (mean treatment difference -0.30; 95% CI -0.56, -0.04; p = 0.025). Compared to lixisenatide, liraglutide recipients were 2.5 times more likely to achieve HbA1c 1% HbA1c reduction (HR 1.29; p = 0.0002). BMI and SBP reductions were greater for the liraglutide group but results were not significant. HCRU was comparable between treatment groups. CONCLUSION: These results from the THIN database indicate that liraglutide treatment provided better outcomes related to glycemic control. FUNDING: Novo Nordisk

DNA methylation predicts age and provides insight into exceptional longevity of bats

This work was supported by a Paul G. Allen Frontiers Group grant to S.H., the University of Maryland, College of Computer, Mathematical and Natural Sciences to G.S.W., an Irish Research Council Consolidator Laureate Award to E.C.T., a UKRI Future Leaders Fellowship (MR/T021985/1) to S.C.V. and a Discovery Grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada to P.A.F. S.C.V. and P.D. were supported by a Max Planck Research Group awarded to S.C.V. by the Max Planck Gesellschaft, and S.C.V. and E.Z.L. were supported by a Human Frontiers Science Program Grant (RGP0058/2016) awarded to S.C.V. L.J.G. was supported by an NSERC PGS-D scholarship.Exceptionally long-lived species, including many bats, rarely show overt signs of aging, making it difficult to determine why species differ in lifespan. Here, we use DNA methylation (DNAm) profiles from 712 known-age bats, representing 26 species, to identify epigenetic changes associated with age and longevity. We demonstrate that DNAm accurately predicts chronological age. Across species, longevity is negatively associated with the rate of DNAm change at age-associated sites. Furthermore, analysis of several bat genomes reveals that hypermethylated age- and longevity-associated sites are disproportionately located in promoter regions of key transcription factors (TF) and enriched for histone and chromatin features associated with transcriptional regulation. Predicted TF binding site motifs and enrichment analyses indicate that age-related methylation change is influenced by developmental processes, while longevity-related DNAm change is associated with innate immunity or tumorigenesis genes, suggesting that bat longevity results from augmented immune response and cancer suppression.Publisher PDFPeer reviewe

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Sensory Communication

Contains table of contents on Section 2, an introduction, reports on eleven research projects and a list of publications.National Institutes of Health Grant 5 R01 DC00117National Institutes of Health Grant 5 R01 DC00270National Institutes of Health Contract 2 P01 DC00361National Institutes of Health Grant 5 R01 DC00100National Institutes of Health Contract 7 R29 DC00428National Institutes of Health Grant 2 R01 DC00126U.S. Air Force - Office of Scientific Research Grant AFOSR 90-0200U.S. Navy - Office of Naval Research Grant N00014-90-J-1935National Institutes of Health Grant 5 R29 DC00625U.S. Navy - Office of Naval Research Grant N00014-91-J-1454U.S. Navy - Office of Naval Research Grant N00014-92-J-181

Communication Biophysics

Contains reports on six research projects.National Institutes of Health (Grant 5 PO1 NS13126)National Institutes of Health (Grant 5 RO1 NS18682)National Institutes of Health (Grant 5 RO1 NS20322)National Institutes of Health (Grant 5 R01 NS20269)National Institutes of Health (Grant 5 T32NS 07047)Symbion, Inc.National Science Foundation (Grant BNS 83-19874)National Science Foundation (Grant BNS 83-19887)National Institutes of Health (Grant 6 RO1 NS 12846)National Institutes of Health (Grant 1 RO1 NS 21322

Tsunami hazard assessment of coastal South Africa based on mega-earthquakes of remote subduction zones

After the mega-earthquakes and concomitant devastating tsunamis in Sumatra (2004) and Japan (2011), we launched an investigation into the potential risk of tsunami hazard to the coastal cities of South Africa. This paper presents the analysis of the seismic hazard of seismogenic sources that could potentially generate tsunamis, as well as the analysis of the tsunami hazard to coastal areas of South Africa. The subduction zones of Makran, South Sandwich Island, Sumatra, and the Andaman Islands were identified as possible sources of mega-earthquakes and tsunamis that could affect the African coast. Numerical tsunami simulations were used to investigate the realistic and worst-case scenarios that could be generated by these subduction zones. The simulated tsunami amplitudes and run-up heights calculated for the coastal cities of Cape Town, Durban, and Port Elizabeth are relatively small and therefore pose no real risk to the South African coast. However, only distant tsunamigenic sources were considered and the results should therefore be viewed as preliminary.The Nuclear Structural Engineering (Pty) and the National Research Foundation through the Technology and Human Resources for Industry Programme project (THRIP) TP2011061400009.https://link.springer.com/journal/242019-04-01hj2018Geolog